CA209-9JX: Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Sep 10, 2026 - P2 | N=78 | Completed | Sponsor: Dana-Farber Cancer Institute | Active, not recruiting ➔ Completed
IO biomarker • Trial completion • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA • ER • HER-2 • PD-L1 • PGR
|